Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Army has granted $2,075m two-year funding for Oxygen Biotherapeutics for the study of Oxycyte PFC emulsion as a therapeutic intervention as a treatment for the reduction of brain damage in victims of traumatic brain injury (TBI).
Subscribe to our email newsletter
Oxygen Biotherapeutics said that the preclinical trials which they will conduct with the support of this grant will investigate the effects of Oxycyte on the immune system, platelet function and distribution ao as to determine the safety profile of Oxycyte.
Additionally, the trials will also assess the safety and efficacy of platelet transfusion, which can be necessary for patients with TBI and related polytrauma.
Oxygen Biotherapeutics chairman and CEO Chris Stern said they are proud to work with the US Army to develop new treatments that will benefit their soldiers, as well as civilians.
"We believe this research grant will give us the important information we need to move Oxycyte down the clinical development path,"Stern said.